Pharming Group (PHAR) and The Competition Critical Survey

Pharming Group (NASDAQ:PHAR – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare Pharming Group to related companies based on the strength of its dividends, earnings, profitability, risk, analyst recommendations, institutional ownership and valuation.

Valuation & Earnings

This table compares Pharming Group and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Pharming Group $386.75 million $2.85 million 39.38
Pharming Group Competitors $755.30 million $11.71 million -18.77

Pharming Group’s peers have higher revenue and earnings than Pharming Group. Pharming Group is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Pharming Group and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pharming Group 6.23% 8.70% 4.93%
Pharming Group Competitors -12,224.09% -202.33% -31.23%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Pharming Group and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pharming Group 0 2 3 0 2.60
Pharming Group Competitors 9923 15313 45674 1602 2.54

Pharming Group presently has a consensus target price of $39.67, indicating a potential upside of 214.81%. As a group, “Biotechnology” companies have a potential upside of 126.38%. Given Pharming Group’s stronger consensus rating and higher possible upside, analysts plainly believe Pharming Group is more favorable than its peers.

Risk and Volatility

Pharming Group has a beta of -0.05, meaning that its share price is 105% less volatile than the S&P 500. Comparatively, Pharming Group’s peers have a beta of -1.84, meaning that their average share price is 284% less volatile than the S&P 500.

Insider and Institutional Ownership

0.0% of Pharming Group shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 2.1% of Pharming Group shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Pharming Group beats its peers on 7 of the 13 factors compared.

Pharming Group Company Profile

(Get Free Report)

Pharming Group N.V. is a biotechnology company headquartered in Leiden, the Netherlands, that develops and commercializes medicines for rare and underserved diseases. Founded in 1988, the company has built its business around treatments for disorders involving the immune system. Its marketed products include Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, and Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.